Thalidomide--a revival story.

One of the most devastating tragedies of modern medicine was set into motion by the over-the-counter marketing of thalidomide in Europe during the late 1950s for the treatment of morning sickness. The drug was withdrawn in the 1960s after the appearance of reports of teratogenicity and phocomelia associated with its use. The recent return of thalidomide stems from the broad spectrum of its pharmacologic and immunologic effects.1 Thalidomide has been approved by the Food and Drug Administration for the treatment of erythema nodosum leprosum, an inflammatory manifestation of leprosy,2 and potential therapeutic applications span a wide spectrum of other diseases. . . .

[1]  G. Kaplan,et al.  The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. , 1993, The Journal of infectious diseases.

[2]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[3]  Mike Clarke,et al.  Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Haslett,et al.  Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset , 1998, The Journal of experimental medicine.

[5]  B. Hales.  Thalidomide on the comeback trail , 1999, Nature Medicine.

[6]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[7]  T. Grogan,et al.  Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. , 1999, Cancer research.

[8]  D. Ribatti,et al.  Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma , 1999, British Journal of Cancer.

[9]  W. Dalton,et al.  Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines , 1999 .

[10]  D. Ribatti,et al.  Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. , 1999, Blood.

[11]  R. Schlossman,et al.  Bone marrow transplantation in multiple myeloma. , 1999, Current opinion in oncology.

[12]  P. Haslett,et al.  Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.

[13]  P. L. Bergsagel,et al.  Multiple myeloma: increasing evidence for a multistep transformation process. , 1998, Blood.

[14]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[15]  S. Handt,et al.  Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. , 1996, Immunopharmacology.

[16]  P. G. Wells,et al.  Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity , 1999, Nature Medicine.

[17]  Judah Folkman,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994 .